Dexcom (Nasdaq:DXCM) announced today that its board of directors approved a four-for-one forward split of the company’s common stock.
San Diego-based Dexcom’s stock split remains contingent upon stockholder approval of a restated certificate of incorporation. Approval of that would increase the number of authorized shares of common stock from 200 million to 800 million.
According to a news release, approval of the stock split from Dexcom’s stockholders would lead to each share of common stock outstanding on May 19, 2022 — the date of Dexcom’s 2022 annual meeting of stockholders — being split into four shares of common stock.
Dexcom expects trading to begin on a split-adjusted basis on June 10, 2022.